secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001104659-25-118863
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Carisma voluntarily delisting from Nasdaq, terminating SEC reporting; appoints new CEO for wind-down
--------------------------------------------------------------------------------

- Board approved voluntary delisting from Nasdaq; Form 25 expected Dec 10; delisting effective 10 days later.
- Company to file Form 15 to suspend and terminate SEC reporting obligations under Sections 13 and 15(d).
- Steven Kelly appointed interim CEO (consulting) at $350/hour through Dec 31, 2025.
- Craig Jalbert to become CEO, President, Treasurer, Secretary and director Jan 1, 2026; $50K/year via his firm.
- Three directors and VP Finance McAndrew resigning effective Dec 31, 2025; no disagreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925118863/0001104659-25-118863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925118863/tm2532811d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-118863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer